Mr. Gilles Gagnon reports

CEAPRO ANNOUNCES NEXT PHASE OF RESEARCH COLLABORATION WITH THE ANGIOGENESIS FOUNDATION

Ceapro Inc. has expanded its collaboration with the Angiogenesis Foundation to conduct research on characterizing healing dynamics and molecular profiling of tissue regeneration stimulated by oat-derived bioactives.

This next research phase is an extension of previous studies demonstrating that Ceapro's products have biological activity. Work presented at the Annual Meeting of the Wound Healing Society (WHS) in April 2023 showed that oat-based beta glucan (BG) and avenanthramides (AV) reduce scar formation, inhibit inflammation, recruit stem cells and stimulate angiogenesis in vivo in a statistically significant manner compared to control.

"A deeper understanding of how oat-derived bioactives improve healing performance at the cellular and molecular levels will allow for optimized product design and improved patient outcomes," commented Dr. Vincent W. Li, Chief Scientific Officer of the Angiogenesis Foundation.

The goals of the new study will be to investigate:

1) the impact of AV and BG on the speed of wound healing at different time points;

2) the unique profile of AV and BG on skin healing dynamics;

3) the molecular profile of regenerative tissue repair by single cell RNA analysis; and

4) differential effects of AV and BG on gene expression of the skin during tissue repair.

"While Ceapro has so far evolved in dermatology by providing active ingredients serving the cosmetic sector, additional expected evidence-based results from this study will not only reinforce and/or add claims to existing cosmetics formulations but should further position Ceapro in dermatology along with a pharmaceutical and medical supplies partner who will benefit from additional selling points arising from this unique research program. This is in line with our vision to expand our business model from an active ingredient provider to a life sciences company," commented Gilles R. Gagnon, M.Sc., MBA, President and CEO of Ceapro.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com .